The Enigma of Diagnosis

Heart failure with reduced ejection fraction (HFrEF) presents a complex diagnostic challenge. The symptoms that bring a patient to the clinic are varied and often point to multiple possible diagnoses. Dyspnea, orthopnea, paroxysmal nocturnal dyspnea, fatigue, and ankle swelling are common, but they can arise from a number of different conditions. The clinical picture that emerges from history taking and the physical exam is the cornerstone of assessment, pointing to underlying causes, effective treatment, and even the need for referral for advanced HF care1.

The Role of History Taking and Physical Exam

The physical exam and history taking form the bedrock of the diagnostic process. They can reveal the underlying causes and guide the treatment plan. For instance, the American Heart Association/American College of Cardiology heart failure guidelines highlight the importance of assessing factors such as concurrent illness, medication use, nonadherence to medication or dietary regimen, ongoing substance abuse, and social determinants of health1.

Diagnostic Tests: Beyond the Physical Exam

If the history and physical exam lead to suspicion of HF, the next step is diagnostic testing, initially with biomarkers and cardiac imaging, and then confirmatory invasive imaging. Laboratory evaluation includes a complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, hemoglobin A1c, lipid profile, liver function tests, iron studies, and thyroid-stimulating hormone1.

The Future of HFrEF Diagnosis

The future of HFrEF diagnosis is promising. New research is exploring the cost-effectiveness of adding medications like dapagliflozin and empagliflozin to standard care for patients with HFrEF2,3. These studies suggest that the addition of these medications could improve long-term clinical outcomes and meet conventional cost-effectiveness thresholds.

Conclusion

The diagnosis of HFrEF is a complex process that requires a comprehensive approach, including history taking, physical exam, and diagnostic testing. As medical technology advances, new methods and treatments are being explored to improve the diagnosis and management of this condition.

Reference
  1. Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation
  2. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
  3. Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System’s Perspective in the Asia-Pacific Region